Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

NCT03062007 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Metastatic Breast Cancer

Interventions

DRUG: BI-CON-02

Sponsor

Biointegrator LLC